NCT06802315View on ClinicalTrials.gov

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2032

Conditions
Acute Myeloid Leukemia, Relapsed, AdultAcute Myeloid Leukemia RefractoryChronic Myeloid Leukemia - Accelerated PhaseMyelodysplastic Syndromes
Interventions
RADIATION

Intensity modulated total marrow irradiation

"See Treatment Regimen"

DRUG

Cyclophosphamide (CTX)

This study will determine the safety of the combination of Total Marrow Irradiation (TMI) and Post-Transplant Cyclophosphamide using a myeloablative fludarabine and iv targeted busulfan (Flu/Bu4) conditioning regimen.

DRUG

Fludarabine (Fludara)

chemotherapy conditioning

DRUG

Busulfan (conditioning for ALLO Transplant)

chemotherapy conditioning

Trial Locations (1)

60612

RECRUITING

University of Illinois Cancer Center, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER